Research graph
References from Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1186/2045-3329-2-14
10.1186/2045-3329-2-14 · External reference
10.1016/j.suc.2008.03.008
10.1016/j.suc.2008.03.008 · External reference
10.1038/s41392-021-00647-8
10.1038/s41392-021-00647-8 · External reference
10.1093/annonc/mdp415
10.1093/annonc/mdp415 · External reference
10.1002/1097-0142(19930715)72:2<486::aid-cncr2820720226>3.0.co;2-r
10.1002/1097-0142(19930715)72:2<486::aid-cncr2820720226>3.0.co;2-r · External reference
10.1634/theoncologist.2018-0641
10.1634/theoncologist.2018-0641 · External reference
10.1016/j.currproblcancer.2019.06.005
10.1016/j.currproblcancer.2019.06.005 · External reference
Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up☆
10.1016/j.annonc.2021.07.006 · 2021 · External reference
10.1186/s13045-024-01580-3
10.1186/s13045-024-01580-3 · External reference
10.1002/cncr.35906
10.1002/cncr.35906 · External reference
10.1016/s1470-2045(14)70063-4
10.1016/s1470-2045(14)70063-4 · External reference
10.1016/s0140-6736(12)60651-5
10.1016/s0140-6736(12)60651-5 · External reference
10.3389/fonc.2021.664853
10.3389/fonc.2021.664853 · External reference
10.1158/1078-0432.ccr-23-3983
10.1158/1078-0432.ccr-23-3983 · External reference
10.1158/1078-0432.ccr-17-3766
10.1158/1078-0432.ccr-17-3766 · External reference
10.3892/ol.2022.13489
10.3892/ol.2022.13489 · External reference
10.1126/science.1104819
10.1126/science.1104819 · External reference
10.1038/s12276-023-01114-w
10.1038/s12276-023-01114-w · External reference
10.7150/thno.72800
10.7150/thno.72800 · External reference
Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy
10.3389/fimmu.2023.1291530 · 2023 · External reference
10.1016/s1470-2045(17)30624-1
10.1016/s1470-2045(17)30624-1 · External reference
10.1016/s1470-2045(18)30006-8
10.1016/s1470-2045(18)30006-8 · External reference
10.1056/nejmoa2303383
10.1056/nejmoa2303383 · External reference
10.1002/14651858.ed000142
10.1002/14651858.ed000142 · External reference
10.1136/bmj.n71
10.1136/bmj.n71 · External reference
10.1148/rycan.2021210008
10.1148/rycan.2021210008 · External reference
10.1016/s1470-2045(17)30074-8
10.1016/s1470-2045(17)30074-8 · External reference
10.3163/1536-5050.104.3.014
10.3163/1536-5050.104.3.014 · External reference
10.1186/s13643-016-0384-4
10.1186/s13643-016-0384-4 · External reference
10.1046/j.1445-2197.2003.02748.x
10.1046/j.1445-2197.2003.02748.x · External reference
10.1136/ebmental-2019-300117
10.1136/ebmental-2019-300117 · External reference
Unresolved reference
External reference
10.1007/s40279-023-01927-9
10.1007/s40279-023-01927-9 · External reference
10.1158/2326-6066.cir-25-0491
10.1158/2326-6066.cir-25-0491 · External reference
10.1177/17588359241276968
10.1177/17588359241276968 · External reference
10.2147/ijgm.s379269
10.2147/ijgm.s379269 · External reference
10.2147/ott.s365506
10.2147/ott.s365506 · External reference
10.1158/1078-0432.ccr-22-0871
10.1158/1078-0432.ccr-22-0871 · External reference
Efficacy and safety of the combination of anlotinib and envafolimab in the treatment of unresectable or metastatic liposarcoma: findings from a single-center retrospective study
10.3389/fonc.2024.1502945 · 2024 · External reference
10.1158/1078-0432.ccr-24-2444
10.1158/1078-0432.ccr-24-2444 · External reference
10.3390/cancers15061643
10.3390/cancers15061643 · External reference
10.1200/jco.2019.37.15_suppl.11015
10.1200/jco.2019.37.15_suppl.11015 · External reference
10.1002/cncr.27624
10.1002/cncr.27624 · External reference
10.1016/j.esmoop.2024.103995
10.1016/j.esmoop.2024.103995 · External reference
10.2340/1651-226x.2025.43135
10.2340/1651-226x.2025.43135 · External reference
10.3390/cancers15082287
10.3390/cancers15082287 · External reference
Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations
10.1177/1758834017712963 · 2017 · External reference
10.1016/j.cpt.2024.02.001
10.1016/j.cpt.2024.02.001 · External reference
10.1186/s13045-018-0664-7
10.1186/s13045-018-0664-7 · External reference
10.1016/j.intimp.2023.110785
10.1016/j.intimp.2023.110785 · External reference
10.3390/cancers15030700
10.3390/cancers15030700 · External reference
10.1007/s12672-024-01492-1
10.1007/s12672-024-01492-1 · External reference
10.1016/s1470-2045(19)30153-6
10.1016/s1470-2045(19)30153-6 · External reference
10.1038/s41467-024-44875-2
10.1038/s41467-024-44875-2 · External reference
10.1158/1078-0432.ccr-24-2519
10.1158/1078-0432.ccr-24-2519 · External reference
10.1200/jco.2015.62.4734
10.1200/jco.2015.62.4734 · External reference
10.1016/s0140-6736(15)01283-0
10.1016/s0140-6736(15)01283-0 · External reference
10.1016/s1470-2045(16)30507-1
10.1016/s1470-2045(16)30507-1 · External reference
10.1186/s40364-023-00513-5
10.1186/s40364-023-00513-5 · External reference
10.1158/1078-0432.ccr-19-1824
10.1158/1078-0432.ccr-19-1824 · External reference
10.1158/0008-5472.can-23-2115
10.1158/0008-5472.can-23-2115 · External reference
10.3389/fimmu.2021.775761
10.3389/fimmu.2021.775761 · External reference
10.3390/ijms22147518
10.3390/ijms22147518 · External reference
10.3390/ijms24086926
10.3390/ijms24086926 · External reference
10.6004/jnccn.2022.0035
10.6004/jnccn.2022.0035 · External reference
10.1093/oncolo/oyaf337
10.1093/oncolo/oyaf337 · External reference
10.1002/1097-0142(19930715)72:2<486::aid-cncr2820720226>3.0.co;2-r
10.1002/1097-0142(19930715)72:2<486::aid-cncr2820720226>3.0.co;2-r · ExternalCitation · doi-reference
10.1002/14651858.ed000142
10.1002/14651858.ed000142 · ExternalCitation · doi-reference
10.1002/cncr.27624
10.1002/cncr.27624 · ExternalCitation · doi-reference
10.1002/cncr.35906
10.1002/cncr.35906 · ExternalCitation · doi-reference
10.1007/s12672-024-01492-1
10.1007/s12672-024-01492-1 · ExternalCitation · doi-reference
10.1007/s40279-023-01927-9
10.1007/s40279-023-01927-9 · ExternalCitation · doi-reference
Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up☆
10.1016/j.annonc.2021.07.006 · ExternalCitation · doi-reference
10.1016/j.cpt.2024.02.001
10.1016/j.cpt.2024.02.001 · ExternalCitation · doi-reference
10.1016/j.currproblcancer.2019.06.005
10.1016/j.currproblcancer.2019.06.005 · ExternalCitation · doi-reference
10.1016/j.esmoop.2024.103995
10.1016/j.esmoop.2024.103995 · ExternalCitation · doi-reference
10.1016/j.intimp.2023.110785
10.1016/j.intimp.2023.110785 · ExternalCitation · doi-reference
10.1016/j.suc.2008.03.008
10.1016/j.suc.2008.03.008 · ExternalCitation · doi-reference
10.1016/s0140-6736(12)60651-5
10.1016/s0140-6736(12)60651-5 · ExternalCitation · doi-reference
10.1016/s0140-6736(15)01283-0
10.1016/s0140-6736(15)01283-0 · ExternalCitation · doi-reference
10.1016/s1470-2045(14)70063-4
10.1016/s1470-2045(14)70063-4 · ExternalCitation · doi-reference
10.1016/s1470-2045(16)30507-1
10.1016/s1470-2045(16)30507-1 · ExternalCitation · doi-reference
10.1016/s1470-2045(17)30074-8
10.1016/s1470-2045(17)30074-8 · ExternalCitation · doi-reference
10.1016/s1470-2045(17)30624-1
10.1016/s1470-2045(17)30624-1 · ExternalCitation · doi-reference
10.1016/s1470-2045(18)30006-8
10.1016/s1470-2045(18)30006-8 · ExternalCitation · doi-reference
10.1016/s1470-2045(19)30153-6
10.1016/s1470-2045(19)30153-6 · ExternalCitation · doi-reference
10.1038/s12276-023-01114-w
10.1038/s12276-023-01114-w · ExternalCitation · doi-reference
10.1038/s41392-021-00647-8
10.1038/s41392-021-00647-8 · ExternalCitation · doi-reference
10.1038/s41467-024-44875-2
10.1038/s41467-024-44875-2 · ExternalCitation · doi-reference
10.1046/j.1445-2197.2003.02748.x
10.1046/j.1445-2197.2003.02748.x · ExternalCitation · doi-reference
10.1056/nejmoa2303383
10.1056/nejmoa2303383 · ExternalCitation · doi-reference
10.1093/annonc/mdp415
10.1093/annonc/mdp415 · ExternalCitation · doi-reference
10.1093/oncolo/oyaf337
10.1093/oncolo/oyaf337 · ExternalCitation · doi-reference
10.1126/science.1104819
10.1126/science.1104819 · ExternalCitation · doi-reference
10.1136/bmj.n71
10.1136/bmj.n71 · ExternalCitation · doi-reference
10.1136/ebmental-2019-300117
10.1136/ebmental-2019-300117 · ExternalCitation · doi-reference
10.1148/rycan.2021210008
10.1148/rycan.2021210008 · ExternalCitation · doi-reference
10.1158/0008-5472.can-23-2115
10.1158/0008-5472.can-23-2115 · ExternalCitation · doi-reference
10.1158/1078-0432.ccr-17-3766
10.1158/1078-0432.ccr-17-3766 · ExternalCitation · doi-reference
10.1158/1078-0432.ccr-19-1824
10.1158/1078-0432.ccr-19-1824 · ExternalCitation · doi-reference
10.1158/1078-0432.ccr-22-0871
10.1158/1078-0432.ccr-22-0871 · ExternalCitation · doi-reference
10.1158/1078-0432.ccr-23-3983
10.1158/1078-0432.ccr-23-3983 · ExternalCitation · doi-reference
10.1158/1078-0432.ccr-24-2444
10.1158/1078-0432.ccr-24-2444 · ExternalCitation · doi-reference
10.1158/1078-0432.ccr-24-2519
10.1158/1078-0432.ccr-24-2519 · ExternalCitation · doi-reference
10.1158/2326-6066.cir-25-0491
10.1158/2326-6066.cir-25-0491 · ExternalCitation · doi-reference
Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations
10.1177/1758834017712963 · ExternalCitation · doi-reference
10.1177/17588359241276968
10.1177/17588359241276968 · ExternalCitation · doi-reference
10.1186/2045-3329-2-14
10.1186/2045-3329-2-14 · ExternalCitation · doi-reference
10.1186/s13045-018-0664-7
10.1186/s13045-018-0664-7 · ExternalCitation · doi-reference
10.1186/s13045-024-01580-3
10.1186/s13045-024-01580-3 · ExternalCitation · doi-reference
10.1186/s13643-016-0384-4
10.1186/s13643-016-0384-4 · ExternalCitation · doi-reference
10.1186/s40364-023-00513-5
10.1186/s40364-023-00513-5 · ExternalCitation · doi-reference
10.1200/jco.2015.62.4734
10.1200/jco.2015.62.4734 · ExternalCitation · doi-reference
10.1200/jco.2019.37.15_suppl.11015
10.1200/jco.2019.37.15_suppl.11015 · ExternalCitation · doi-reference
10.1634/theoncologist.2018-0641
10.1634/theoncologist.2018-0641 · ExternalCitation · doi-reference
10.2147/ijgm.s379269
10.2147/ijgm.s379269 · ExternalCitation · doi-reference
10.2147/ott.s365506
10.2147/ott.s365506 · ExternalCitation · doi-reference
10.2340/1651-226x.2025.43135
10.2340/1651-226x.2025.43135 · ExternalCitation · doi-reference
10.3163/1536-5050.104.3.014
10.3163/1536-5050.104.3.014 · ExternalCitation · doi-reference
10.3389/fimmu.2021.775761
10.3389/fimmu.2021.775761 · ExternalCitation · doi-reference
Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy
10.3389/fimmu.2023.1291530 · ExternalCitation · doi-reference
10.3389/fonc.2021.664853
10.3389/fonc.2021.664853 · ExternalCitation · doi-reference
Efficacy and safety of the combination of anlotinib and envafolimab in the treatment of unresectable or metastatic liposarcoma: findings from a single-center retrospective study
10.3389/fonc.2024.1502945 · ExternalCitation · doi-reference
10.3390/cancers15030700
10.3390/cancers15030700 · ExternalCitation · doi-reference
10.3390/cancers15061643
10.3390/cancers15061643 · ExternalCitation · doi-reference
10.3390/cancers15082287
10.3390/cancers15082287 · ExternalCitation · doi-reference
10.3390/ijms22147518
10.3390/ijms22147518 · ExternalCitation · doi-reference
10.3390/ijms24086926
10.3390/ijms24086926 · ExternalCitation · doi-reference
10.3892/ol.2022.13489
10.3892/ol.2022.13489 · ExternalCitation · doi-reference
10.6004/jnccn.2022.0035
10.6004/jnccn.2022.0035 · ExternalCitation · doi-reference
10.7150/thno.72800
10.7150/thno.72800 · ExternalCitation · doi-reference
